CLL/SLL First-Line Treatments and Second Cancers. What Recent Research Shows
A common concern for people living with CLL/SLL is whether treatment increases the risk of developing another cancer. Recent research offers reassuring news.
Visit our CLL Information and Resource CentreA guide for patients looking for answers to their CLL questions on the Internet. |
A common concern for people living with CLL/SLL is whether treatment increases the risk of developing another cancer. Recent research offers reassuring news.
What do Canadian hematologists see as the biggest opportunities—and challenges—of time-limited treatment for CLL in previously untreated patients?
If you’re living with CLL, a new resource can help you better understand and manage infection risk. The booklet ‘Navigating Immune Challenges in CLL: Infection Prevention and Management’ provides practical guidance on preventing infections and knowing what to do if one occurs.
Research suggests that gentle movement, even in small amounts, may help people living with CLL improve their energy, reduce symptoms and maintain quality of life. This may be especially true for those who feel the most fatigue or physical limitations.
At 33, I was confronted with two diagnoses that reshaped every assumption I had about my future. I learned I would live with Chronic Lymphocytic Leukemia for the rest of my life, and I was told I would not be able to have biological children.
A new Canadian website is making it easier for cancer patients to explore clinical trial options. Search for trials across Canada using simple keywords and filters or get help navigating the site through the Canadian Cancer Society’s Cancer Information Helpline.
In late 2025, the American Society of Hematology (ASH) conference highlighted many important updates for people living with Chronic Lymphocytic Leukemia (CLL), including emerging treatment approaches, long-term follow-up on existing therapies.
Calling all patients and care partners to share their experiences to improve patient outcomes. The 2026 Global Patient Survey on Lymphoma & CLL (GPS) is the only opportunity for the worldwide lymphoma and CLL community of patients and care partners to share insights…
Pirtobrutinib (brand name Jaypirca) has been approved by Health Canada and is available for use as monotherapy for the treatment of adult patients in Canada with CLL/SLL who have received at least two prior lines of therapy…
Richter transformation (RT) is a rare but serious change that can happen in people with chronic lymphocytic leukemia (CLL), where the slower-growing CLL becomes a more aggressive form of lymphoma.
Combination treatments using drugs that target different CLL mechanisms have shown promising results for patients in clinical trials. And the great news is that some treatments that combine BTK and BCL2 inhibitors are now being approved as first line treatment options in Canada.
There is some good news to share on the treatment front! Since spring 2025, six provinces in Canada have made publicly funded Ibrutinib + Venetoclax (I+V) combination therapy available for previously untreated CLL patients.
Understanding your preferred communication style can significantly enhance your relationship with your healthcare team and empower you to make informed decisions about your health.
The development of a new cancer drug at the University of Alberta shows both the promise and the challenges of drug development.
Over a ten-year span, the treatment landscape for chronic lymphocytic leukemia (CLL) has improved dramatically.
As a CLL patient, taking an active role in your healthcare can be a game-changer – and doing your own research is a powerful way to start.
With a flare up of measles cases in Canada, how concerned do we need to be when we have an immune system weakened by CLL?
For CLL patients at any age, the idea of running out of treatment options is a big concern. This is especially true for those who are younger and/or raising a family.
Changes are afoot in CLL Canada’s online presence, with a new format for our bulletin, an updated website and French language pages.
Patients and care partners will hear from leading experts in CLL research, treatment and care and share experiences with one another. April 24 to 26, 2025 in Niagara Falls, Ontario.
